M J Gray

Summary

Affiliation: OSI Pharmaceuticals
Country: USA

Publications

  1. pmc Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver
    M J Gray
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 27:7192-200. 2008
  2. pmc Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells
    J S Wey
    Department of Surgical Oncology, Unit 444, The University of Texas, MD Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Br J Cancer 93:233-41. 2005

Collaborators

  • W Liu
  • A K Sood
  • J S Wey
  • G E Gallick
  • A Belcheva
  • L M Ellis
  • D B Evans
  • O Stoeltzing
  • M F McCarty
  • F Fan
  • R Somcio
  • M Klagsbrun

Detail Information

Publications2

  1. pmc Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver
    M J Gray
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 27:7192-200. 2008
    ..006). We conclude that Id2 is upregulated in CRC, and is important in promoting cell survival. In vivo targeting of Id2 by siRNA establishes that it is a valid therapeutic target where its expression occurs...
  2. pmc Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells
    J S Wey
    Department of Surgical Oncology, Unit 444, The University of Texas, MD Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Br J Cancer 93:233-41. 2005
    ..Targeting NRP-1 in pancreatic cancer cells may downregulate survival signalling pathways and increase sensitivity to chemotherapy...